Woodline Partners LP Acquires 4.4% Stake in Aligos Therapeutics, Inc.

Woodline Partners LP has filed a Schedule 13G/A for Aligos Therapeutics, Inc. (ALGS), reporting a beneficial ownership of 239,362 shares of Voting Common Stock. This position represents approximately 4.4% of the company's outstanding shares, based on 5,387,807 shares reported as of March 2, 2026. The reported total includes 62,000 shares issuable upon the exercise of warrants. Woodline Partners LP, a Delaware limited partnership, serves as the investment adviser to Woodline Master Fund LP, which directly holds the securities. The filing indicates an increase from a previous 0% ownership level as of the last reported period. The reporting person has sole voting and dispositive power over all reported shares. This amendment (Amendment No. 4) confirms that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The event triggering this filing occurred on March 31, 2026, and the filing was formally submitted on May 15, 2026.